Taking Spatial Toward the Clinic: DeciBio’s Q&A with Sandy Au of NeoGenomics
Blog originally posted on Decibio Insights here.
Is IHC going to exhaust our archival blocks the way single gene testing used to?
Over the past year we have seen unprecedented demand for IHC assay development services with the goal of creating a prototype CDx assay.
NeoGenomics announces speaker program, ‘Minimal Residual Disease in Colorectal Cancer’
NeoGenomics is pleased to announce a speaker program titled ‘Minimal Residual Disease in Colorectal Cancer.’
IVDR at NeoGenomics
With the recent application of IVDR on May 26, 2022, there are new regulatory standards that oversee the sales and use of IVDs for the EU.
NeoGenomics Lab Operations | Hurricane Ian
Important Announcement
NeoGenomics Lab Operations | Hurricane Ian
Orphan CDx assays
Drug development is rapidly outpacing our ability to bring companion diagnostics to market.
MultiOmyx 101: An Introduction to Multiplexing Technology
Cancer claims more than half a million lives each year in the United States alone.
Anna Juncker-Jensen